In agreement with the senolytic results in vitro, oral administration of dasatinib and quercetin to Kif13b-/- mice significantly reversed AAA severity when compared to solvent-treated Kif13b-/- mice (Figure 8G-L), further suggesting that restoring myeloid KIF13B or eliminating senescent cells mitigates AAA progression caused by Kif13b deficiency, positioning KIF13B as a key protector against macrophage senescence-driven vascular pathology. This evidence concerns the gene KIF13B and triple-A syndrome.